Introduction
Carnitine palmitoyl transferase I (CPT I), a transmembrane enzyme of the mitochondrial moiety from a long-chain acyl-CoA ester to carnitine to form a long-chain acyl-carnitine ester, which can then enter the mitochondrion and undergo /?-oxidation [1,2]. The enzyme is a potential site for the regulation of/3-oxidation flux via its physiological inhibitor, malonyl-CoA [2,3] and is widely assumed to be the rate-limiting step in the p-oxidation of long-chain fatty acids in the heart and other tissues [l-31. However, the concentration of malonyl-CoA in the heart is estimated to be in the range 1-10 pM [3-71. This greatly exceeds the IC,, of heart C P T I for malonyl-CoA [8] , so it is difficult to see how 8- oxidation proceeds in cardiac tissue if C P T I activity is rate-limiting for /&oxidation. A similar situation exists in skeletal muscle, in which the IC,, for malonyl-CoA is even lower.
Among the possibilities to account for this observation are the following: (1) there is a malonyl-CoA-insensitive C P T I activity in the outer mitochondrial membrane (2) much of the measured malonyl-CoA is intramitochondrial or bound and therefore not available to inhibit C P T I ; and (3) C P T I is not rate-limiting for Boxidation in the heart.
In this review we shall attempt to clarify this issue by considering each of the above.
Outer membrane carnitine palmitoyl transferases in the heart
Both isoforms (liver and muscle) of C P T I are present in the heart [9, 10] . As the two isoforms have very different IC,, values for malonyl-CoA and vary in their relative amounts in the heart during development, heart tissue has an overall IC,, for malonyl-CoA that is intermediate between that of liver and muscle and also varies with development [lo]. However, there are additional factors that can alter the ability of malonyl-CoA to inhibit C P T I in the heart. First, the sensitivity of liver isoform of C P T I to malonyl-CoA is itself acutely regulated in the liver [l 11 and the activity of hepatic C P T I can be modified by the Ca2+/ calmodulin system and/or cytoskeletal components [12, 13] . However, whether the sensitivity to malonyl-CoA or the activity of the liver isoform of C P T I expressed in the heart is altered by the these factors is unknown.
Recently, alternative muscle-CPT I (M-CPT I) splicing isoforms have been demonstrated in both rat [14] and human [15] heart. Although the mRNA species for the two splicing isoforms are expressed in heart, it is not yet known whether there is any steady-state expression of their respective proteins. M-CPT I migrates anomalously on SDS/PAGE (88.2 kDa predicted molecular mass, runs at approx. 82 kDa) [16] and because the predicted molecular mass of the proteins of two splicing variants is close to 82 kDa and the migration of the splicing variants is unknown, it has so far been difficult to quantify the expression of these proteins. The first of these splicing isoforms, C P T I@-2, completely lacks the second transmembrane domain, so it is uncertain whether it can insert correctly into the mitochondria1 outer membrane (Figure 1) [ 14,151. The second splicing isoform, C P T I/3-3, lacks 34 residues towards the N-terminal end of the catalytic region (Figure 1 ) [14, 15] . Much progress has been made in recent years in defining residues in the carnitine acyltransferases that are responsible for inhibitability by malonyl-CoA and etomoxir-CoA, for affinity for carnitine and for catalytic activity [17] [18] [19] [20] [21] [22] [23] . Although both C P T IB-2 and C P T IB-3 maintain the catalytic C-terminus of the enzyme (which contains residues necessary for binding to etomoxir-CoA [17] ) and N-terminal amino acids crucial for malonyl-CoA sensitivity [23] , the catalytic properties and malonyl-CoA sensitivity of the novel isoforms cannot be readily predicted, even if they are expressed and targeted correctly. However, it has been suggested that the splicing isoforms are insensitive to malonyl-CoA and this allows 8-oxidation to take place even in the presence of significant [malonyl-CoA] [14,15] and that this accounts for the incomplete inhibition of C P T I by malonyl-CoA that has been observed in cardiac myocytes [7] . Thus the physiological relevance of the novel M-CPT I splicing variants is an area that needs to be addressed.
Formation, subcellular localization and disposal of cardiac malonyl-CoA
The major route for formation of malonyl-CoA in the heart, as in liver and other tissues, is by the from that predominant in liver. However, it is possible that some of the malonyl-CoA measured in heart might be intramitochondrial owing to the action of propionyl-CoA carboxylase on acetyl- It is also possible that the binding of extramitochondrial malonyl-CoA to mitochondrial low-affinity sites [37] or to cytosolic binding proteins such as that described in liver [38] would also prevent malonyl-CoA from inhibiting C P T I.
For a discussion of the role of acetyl-CoA 
Is CPT I activity rate-limiting for /?-oxidation?
The concept of a single rate-limiting step in a pathway has been questioned; in most pathways, control is shared between several steps [39] . By using the techniques of metabolic control analysis, C P T I was found to exert significant control (flux control coefficient in the range 0.5-1) over 8-oxidation flux in hepatocytes [11, [40] [41] [42] , liver mitochondria [43] and astrocytes [44] , although it was not found to be rate-limiting. Because control analysis of /?-oxidation in heart or skeletal muscle has not been undertaken, we set out to determine the control coefficient of C P T I over 8-oxidation flux in heart mitochondria. We chose to examine neonatal heart mitochondria because 8-oxidation flux increases rapidly in the heart during the fetal-neonatal transition [45] and this is the period during which the two isoforms (liver and muscle) of C P T I are changing in relative amounts and the presence of L-CPT I is thought to allow 8-oxidation to take place in the face of high [malonylCoA] [9] . Mitochondria were used as a model system because it is important to undertake control analysis in systems in which unambiguous measures of flux and enzyme activity can be made. 
Inhibition of CPT I activity
In addition, by using heart mitochondria in state 3.5, we modelled mitochondria in the heart working at a high rate, whereas although the cardiomyocyte is a useful system with which to explore the relationship between malonyl-CoA concentration and inhibition of C P T I activity, it is not a good system with which to model the relationship between &oxidation flux and C P T I activity in the working heart. Mitochondria were incubated with etomoxir-CoA, which inhibits both liver and muscle isoforms of C P T I. Our results are shown in Figure 3 (curve fitted to the experimental data by the method of Gellerich et al. [46] , raw data to be reported elsewhere). About 50% of C P T I activity could be inhibited before 8-oxidation flux was affected, whereupon C P T I became ratelimiting for 8-oxidation. When C P T I is not inhibited at all, the flux control coefficient of C P T I over 8-oxidation is 0.08f.0.05. These results apparently contradict the assumption that C P T I is the 'rate-limiting step' of mitochondrial p-
oxidation. Several studies have demonstrated correlations between the rate of oxidation of fatty acids in the perfused heart and in isolated myocytes (as well as in skeletal muscle) and the concentration of malonyl-CoA, and between the activities of acetyl-CoA carboxylase, AMPdependent protein kinase and malonyl-CoA decarboxylase [3, 5, 47, 48] . In addition, malonyl-CoA levels in intact cardiomyocytes change very rapidly in response to glucose [27] and the malonyl-CoA concentration in skeletal muscle is well correlated with increases in respiratory quotient (measured by indirect calorimetry) during the starved-re-fed transition and this provides good evidence in vivo for the control of /%oxidation flux in muscle at the level of the malonyl-CoA/CPT I axis [49] . These studies therefore all suggest that C P T I has significant control over 8-oxidation flux in the intact cell or organ or in vivo. Our results and these above observations could be explained by a model in which some malonyl-CoA is bound or intramitochondrial, and the physiological range of extramitochondrial [malonyl-CoA] is such that C P T I has a high flux control coefficient (i.e. the control of 8-oxidation flux in vivo by C P T I is within the grey box indicated on Figure 3 ). Flux control over 8-oxidation would therefore be shared between C P T I and other controls such as control mechanisms such as [Ca"] effects on the utilization of acetyl-CoA in the tricarboxylic acid cycle, the carnitine-acylcarnitine translocase [50, These results immediately suggested that peroxisomes, which were known to contain a fatty acid /?-oxidation system, had a major role in the /?-oxidation of C,,:, and C,,:,. Subsequent studies provided conclusive evidence for this. The second major discovery emphasizing the importance of peroxisomes in humans came in 1983, when Heymans et al. [3] reported the deficiency of plasmalogens, a special type of phospholipid with an alkenyl group at the sn-1 position in tissues from Zellweger patients. Since then much has been learned about the metabolic role of peroxisomes and many functions of peroxi-
